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Background: Published data on prostate magnetic resonance imaging (MRI) during
follow-up of men on active surveillance are lacking. Current guidelines for prostate MRI
reporting concentrate on prostate cancer (PCa) detection and staging. A standardised
approach to prostate MRI reporting for active surveillance will facilitate the robust
collection of evidence in this newly developing area.
Objective: To develop preliminary recommendations for reporting of individual MRI
studies in men on active surveillance and for researchers reporting the outcomes of
cohorts of men having MRI on active surveillance.
Design, setting, and participants: The RAND/UCLA Appropriateness Method was used.
Experts in urology, radiology, and radiation oncology developed a set of 394 statements
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was scored for agreement on a 9-point scale by each panellist prior to a panelmeeting. Each
statement was discussed and rescored at the meeting.
Outcome measurements and statistical analysis: Measures of agreement and consensus
were calculated for each statement. The most important statements, derived from both
group discussion and scores of agreement and consensus, were used to create the Prostate
Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) checklist and
case report form.
Results and limitations: Key recommendations include reporting the index lesion size
using absolute values at baseline and at each subsequent MRI. Radiologists should assess
the likelihood of true change over time (ie, change in size or change in lesion characteristics
on one ormore sequences) on a 1–5 scale. A checklist of items for reporting a cohort of men
on active surveillance was developed. These items were developed based on expert
consensus in many areas in which data are lacking, and they are expected to develop
and change as evidence is accrued.
Conclusions: The PRECISE recommendations are designed to facilitate the development of a
robust evidencedatabase for documenting changes inprostateMRI findings over timeofmen
on active surveillance. If used, theywill facilitate data collection to distinguishmeasurement
error and natural variability in MRI appearances from true radiologic progression.
Patient summary: Few published reports are available on how to use and interpret
magnetic resonance imaging for men on active surveillance for prostate cancer. The
PRECISE panel recommends that data should be collected in a standardised manner so
that natural variation in the appearance and measurement of cancer over time can be
distinguished from changes indicating significant tumour progression.
# 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Please visit www.eu-acme.org/
europeanurology to read and
answer questions on-line.
The EU-ACME credits will
then be attributed
automatically.
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The use of multiparametric magnetic resonance imaging
(MRI) to inform the detection of prostate cancer (PCa) has
grown rapidly in the last few years. Numerous publications
have sought to standardise the conduct and reporting of
prostate MRI [1–3]. Most recently the European Society of
Uroradiology and the American College of Radiology [4]
published the second version of the Prostate Imaging
Reporting andData System (PI-RADS) outlining the conduct,
interpretation, and reporting of prostate MRI. These guide-
lines focus on PCa detection, and the questions asked are
‘‘How likely is it that this man has prostate cancer?’’ and
‘‘How can this best be biopsied?’’
The 2014 UK National Institute for Health and Care
Excellence (NICE) PCa guidelines [5] suggest a role for MRI
in the initial and repeat assessment of men on active
surveillance, although no guidance is offered on imaging
criteria for selection or continuation of surveillance. NICE
recommends MRI and/or biopsy for re-evaluation if there is
‘‘concern over prostate-specific antigen (PSA) kinetics or
clinical assessment.’’ The question asked ofMRI is then ‘‘Has
there been any significant change?’’ To distinguish between
significant change, measurement error, and natural fluctua-
tions in tumour appearance, we need to understand the
natural history of MRI changes over time in men on active
surveillance in terms of change to MRI lesions and so-called
normal MRI findings. Once these data are established,
radiologic thresholds can be set that indicate significant
actionable, clinical change in disease.
Schoots et al reviewed the evidence for MRI in men on
active surveillance [6]. They found a lack of published data
in the use of MRI in active surveillance follow-up. The
European School of Oncology then convened the Prostate
Cancer Radiological Estimation of Change in Sequential
Evaluation (PRECISE) panel to develop recommendations
for MRI in men on active surveillance for PCa. Formalconsensus methodology, including the use of a face-to-face
meeting, was chosen. This technique is helpful to determine
the level of agreement amongst experts and to identify
areas that require further data before agreement can be
reached. The panel’s objective was to develop recommen-
dations for the reporting of individual MRI studies in men
on active surveillance (the PRECISE report form) and for
researchers reporting the outcomes of cohorts of men
having MRI on active surveillance (the PRECISE checklist).
2. Materials and methods
2.1. Study design
We used the RAND/UCLA Appropriateness Method [7]. A core group
(C.M.M., I.G.S., A.K., C.A., and F.G.) developed a draft set of 350 statements
and sent them to all panel members for modification. Statements could
be revised, removed, or added at this stage. A revised set of
394 statements was scored by each panel member on a scale of
agreement from 1 to 9, in which 1 indicated strongest disagreement and
9 indicated strongest agreement. These scores were collated, and a
summary of agreement, uncertainty, or disagreement (derived from the
group median score) was calculated for each statement. Calculations to
determine consensus or lack of consensus for each statement were
performed using the RAND/UCLA classical criteria that take into account
the proportion of panellists scoringwithin a given category of agreement
(7–9), uncertainty (4–6), or disagreement (1–3). For a statement to have
consensus, a clear majority scoring in that category is needed.
A chair (P.A.) who did not participate in scoring convened a panel
meeting. A graphic representation of the group response was presented
for each statement that included the group median score and the degree
of consensus (Fig. 1). Each statement was discussed. Some statements
were modified or removed; others were added as a result of the
discussions. Following discussion, each statement was rescored anony-
mously by each panel member. Following the meeting, the individual
panellist scores were collated, and the degree of agreement and
consensus was calculated for each statement. The collated scores and
the content of the discussion were used to develop the PRECISE checklist
of reporting criteria for studies of MRI in men on active surveillance and
[(Fig._1)TD$FIG]
Fig. 1 – Graphic representation of the group response for four statements showing (a) agreement and consensus (group median score: 8), (b)
uncertainty and consensus (group median score: 5), (c) agreement and no consensus (group median score: 7.5), and (d) disagreement and no
consensus (group median score: 3).
E U RO P E AN URO LOG Y 7 1 ( 2 0 1 7 ) 6 4 8 – 6 5 5650the PRECISE case report template form to report MRI at baseline or
follow-up in these men.
The checklist provides a guide for authors in preparing a manuscript
for publication and for reviewers and editors when assessing manu-
scripts. The case report template form is suitable for clinical use allowing
communication of imaging findings and their likely relevance to
referring clinicians, and it will also allow data collection to inform the
reporting of cohorts of men.
2.2. Setting and participants
The panel included 10 experts in urology, 8 in radiology, and 1 in
radiation oncology (Supplementary Table 1 summarises panellist
experience). Faculty attending the 2nd European School of Oncology
Active Surveillance February 2016 workshop in Milan, Italy, were
initially approached to join the panel. Additional members not attending













201 (51) 12 (3) 181 (46)
During meeting
(n = 367)
144 (39) 34 (9) 189 (52)members were unable to travel to the meeting and participated by
online conference (B.T. and P.P.) with audio participation and desktop
viewing so they could see all of the presentations.
3. Results
To avoid ambiguous statements and to identify consensus if
it existed, 38 statements were deleted, 56 statements
modified, and 11 statements added during the panel
meeting, giving a final set of 367 statements that were
scored.
During the first round, 201 of 394 statements were
scored with consensus and agreement. Table 1 shows the
scoring during the meeting.
3.1. The PRECISE case report form for reporting a magnetic
resonance study in an individual man on active surveillance
The PRECISE case report form (Fig. 2) includes each item
that should be reported for an individualman having anMRI
at baseline or follow-up during active surveillance.
3.2. The PRECISE checklist for reporting cohorts of men having
magnetic resonance imaging in active surveillance
The PRECISE checklist (Table 2) shows the panel recom-
mendations for reporting a cohort of men who have a
[(Fig._2)TD$FIG]
Fig. 2 – Case report form for reporting of magnetic resonance imaging at baseline and during follow-up in men on active surveillance.
MRI = magnetic resonance imaging; PI-RADS = Prostate Imaging Reporting and Data System; PRECISE = Prostate Cancer Radiological Estimation of
Change in Sequential Evaluation; PSA = prostate-specific antigen; T2W-I = T2-weighted image.
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the checklist were scored with consensus and agreement.
Items were not included in the checklist if they were
scored with disagreement or lack of consensus at the
meeting. Items were grouped together, and all definitive-
ly agreed statements were included. Supplementary
Table 2 describes the full list of items and their scores.
The intention was to develop a comprehensive but not
restrictive set of statements, balancing the need for
clarity and brevity and recognising the variations in
current reporting practice, both in histologic and radio-
logic data.
3.3. Reporting the conduct of magnetic resonance imaging
The PRECISE guidelines are not intended to replace or
competewith the comprehensive guidelines on the conduct
of prostate MRI developed by the Prostate Imaging
Reporting and Data System (PI-RADS) group [4]. The panel
agreed that publications should state whether study MRI
scans were conducted in accordance with contemporary
guidelines and should cite the guidelines used. We
recognise that the conduct of MRI may change over thereporting period of a study because of the longitudinal
nature of active surveillance cohorts.
3.4. Reporting of magnetic resonance imaging
The number of radiologists reporting scans in the study
cohort should be stated. If an individual scan was reported
by more than one radiologist, the use of separate or
consensus reporting should be clarified. When scans were
reported separately, the method used to combine results
should be used (eg, mean of absolute size values at each
time point, mean change in size between scans per
reporter). The format of the radiology report should be
stated (eg, prose, template, and/or diagrammatic reporting,
with andwithout embedded or annotatedMRI images). The
PRECISE case report form was designed to facilitate the
routine collection of clinical and imaging data in a manner
that will allow cohort comparison of men on active
surveillance in a standardised manner. It should be stated
whether the MRI readings were done retrospectively, with
one reading of a set of MRIs from previous time points, or
whether scans were reported contemporaneously, with or
without reference to previous images or reports.
Table 2 – The PRECISE checklist
Item Section of paper Description
1 Title The study should be identified as reporting results from MRI in men on active surveillance, either to identify men as suitable for
AS or as a tool for repeat assessment on AS
2 Introduction The introduction should include a clear statement of the research question or study aim (eg, correlation of pathologic outcomes




The setting, location, and recruitment period and study design (prospective/retrospective) should be reported. It should be made
clear (and citation given) if the report is an update of a previously published cohort
The inclusion and exclusion criteria with the maximum Gleason score, maximum PSA, and the name, version, and citation of an
established AS protocol or risk classification system (where relevant) should be reported
The requirement for confirmatory biopsy, frequency of PSA testing, and the indication and frequency for biopsy, MRI, and any
additional test (eg, genomic classifiers)
Indications for a switch to active treatment should be specified
4 Conduct of
the MRI
Whether or not the MRI conduct met the minimum criteria set by the European Society of Uroradiology and the American College
of Radiologists [4] or other stated guidelines
The field strength and the specific coils used should be stated including a brief description of the sequences
The in-plane resolution and slice thickness of the T2W images should be stated; the image sets analysed for DWI including the
highest b-value acquired and whether the highest b-value was extrapolated or not; the temporal resolution for DCE images
5 Reporting of
the MRI
The number of radiologists reporting scans in the study should be stated
The availability (or not) of clinical information and previous MRI images to the reporting radiologist should be stated
When more than one radiologist reports a scan, it should be stated whether this is done separately or in consensus. When done
separately it should be stated how a summary value was derived (eg, mean absolute values or mean change between scans per
reporter)
The reporting method used (eg, prose vs diagrammatic report, name and version of scoring system) should be given
6 Conduct of the
biopsy
The anatomic approach (transrectal/transperineal) and method of targeting MRI lesions; the use of separate pots for targeted and
systematic cores (if applicable)
The time interval between MRI and biopsy (median and range)
Whether systematic cores are taken in all, and the intended number of systematic cores per prostate and targeted cores per
lesion; whether systematic biopsy was performed blind to MRI findings. The criteria for choosing a lesion to be targeted, whether
the biopsy operator had direct access to the MR images. Where software assistance was used for registration of MRI and
ultrasound images, the manufacturer and model should be stated
7 Patient
characteristics
The age range, baseline PSA, and MRI-derived prostate volume, distribution of Gleason score, and risk categories across the group
and the MCCL. The number of men taking drugs that would affect the hormonal environment of the prostate (eg, 5a-reductase
inhibitors, testosterone) should be recorded
A flowchart of participants showing numbers of men eligible, offered and enrolled in the study, with those who continue on AS




The baseline MRI report should contain the prostate volume measured on T2 W imaging and a likelihood of clinically significant
cancer on a scale of 1–5 for the whole prostate and for each lesion. The likelihood of extraprostatic extension and seminal vesicle
involvement should be reported on a 1–5 scale. The index lesion size should be reported using volume (by planimetry or derived
from three diameters) or measurement of 1 or 2 diameters
9 Follow-up MRI In addition to features reported at baseline, any subsequent MRI report should include the following:
 A score on a 1–5 scale for the likelihood of significant change, along with a description of the change that has given rise to the
score (eg, change in size, change in conspicuity on one or more sequences)
 Any change in likelihood of significant cancer (1–5 scale)
 An increase in suspicion due to extension into seminal vesicles or a suspicious lymph node or bone lesion
 Absolute values of lesion size at baseline and each subsequent scan
 The appearance of any new lesion




Separate reporting of systematic and targeted cores with a MCCL and Gleason grouping per patient irrespective of whether this
was derived from targeted or systematic cores; mean/median number of cores per prostate and per lesion; mean/median number
of lesions per patient where targeted cores were taken
11 Statistical analysis The effect of interreader variability; whether any effect depends on the size of the baseline lesion; whether outliers (very large or
very small lesions) were excluded; how the disappearance of a lesion is handled in the statistical analysis. Where there is
adequate power to do so, univariate and multivariate analysis should be used to assess the added value of a reporting statement
to baseline clinical data; the odds ratio for a single and a combination of unfavourable factors should be given
12 Discussion The clinical applicability of the findings should be discussed, along with the correlation of the observed MRI changes with
traditional tools to measure disease progression (DRE, PSA kinetics, biopsy findings)
AS = active surveillance; DCE = dynamic contrast-enhanced; DRE = digital rectal examination; DWI = diffusion-weighted imaging; MCCL = maximum cancer
core length; MRI = magnetic resonance imaging; PSA = prostate-specific antigen; T2W = T2-weighted.
E U RO P E AN URO LOG Y 7 1 ( 2 0 1 7 ) 6 4 8 – 6 5 56523.5. Reporting of the biopsy at entry to active surveillance
There was agreement and consensus on the use of the
Gleason score, but uncertainty and no consensus on the use
of maximum cancer core length (MCCL) and maximum
number and proportion of cores. Panel members felt that
many cohorts of men on active surveillance will not havehad an MRI-targeted biopsy at study entry and that the
number or proportion of positive cores would be strongly
influenced by the strategy used to perform the biopsies
(standard or targeted to MRI lesions). Reporting the
maximum number of positive cores is a helpful indicator
in a standard random biopsy, but it is less helpful when
oversampling is intended during a targeted biopsy of a
Table 3 – Assessment of likelihood of radiologic progression on magnetic resonance imaging in men on active surveillance
Likert Assessment of likelihood of
radiologic progression
Example
1 Resolution of previous features suspicious on MRI Previously enhancing area no longer enhances
2 Reduction in volume and/or conspicuity of previous
features suspicious on MRI
Reduction in size of previously seen lesion that remains suspicious for clinically
significant disease
3 Stable MRI appearance: no new focal/diffuse lesions Either no suspicious features or all lesions stable in size and appearance
4 Significant increase in size and/or conspicuity of
features suspicious for prostate cancer
Lesion becomes visible on diffusion-weighted imaging; significant increase in
size of previously seen lesion
5 Definitive radiologic stage progression Appearance of extracapsular extension, seminal vesicle involvement, lymph node
involvement, or bone metastasis
MRI = magnetic resonance imaging.
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the radiologist in the clinical setting to know the location of
positive biopsies, although this information would not be
known in a blinded study.
3.6. Reporting of magnetic resonance imaging at baseline and
follow-up
Prostate volume on T2-weighted sequences and PSA density
should be reported. Determination of an assessment of the
likelihood of clinically significant disease on a 1–5 scale is
required for each MRI. The use of the term assessment was
chosen to include both those groups who use PI-RADS (v.1
or v.2) and those who use a 1–5 scale based on overall
clinical impression without predefined characteristics per
sequence (commonly called a Likert scale). The scale used
should be identified.
The highest likelihood of clinically significant cancer of all
separate lesions should provide the likelihood of clinically
significant cancer for the whole prostate. For men with a
visible lesion, the keymetric is the size of the index lesion on
the baselineMRI and at each time point thereafter. The term
index lesion can be used to denote the largest lesion, or the
one with the highest Gleason grade, or the one of highest
suspicion based on MRI criteria [6]. It was noted that not all
men with PCa suitable for active surveillance will have a
visible lesion on MRI. It was agreed that size can be
measured using volume (by planimetry or calculated from
three diameters), by biaxial measurement of maximum
diameters on an axial slice, or by a single measurement of
maximum diameter. The panel felt that as yet there was
insufficient evidence to determine which of the methods for
measuring size was optimal for distinguishing between
natural fluctuation in tumour volume, measurement errors
over time, or true disease progression. Some believed that
planimetry volume would be most accurate; others were
concerned that thiswas too time consuming. For lesions best
seen on functional image sequences (eg, high b-value
images), a single diameter may be more reproducible than
a volume because of the need to use larger voxel sizes in
sequence acquisitions. Comparative data from the same
cohort on the reproducibility of different sizemeasurements
(eg, planimetry volume and biaxial diameter) would be of
great value in exploring this further.
All parameters reported on the baseline MRI should be
reported again on follow-up MRI. In addition, any MRIreport after the baseline MRI report should include an
assessment of the likelihood of significant radiologic
progression from the baseline MRI scan, on a 1–5 scale,
along with a description of the change that has given rise to
that assessment (eg, change in size or change in conspicuity
on one or more sequences). Table 3 shows further details. It
should be noted that there are no robust data on which to
base the threshold for a significant change in size or
conspicuity. The intention is that data collection using the
suggested format will allow such data to be acquired, and
that, in time, thresholds can be set.
3.7. Clinically significant disease in men on active surveillance
It was agreed that Gleason grading and MCCLs were
important determinants of clinically significant disease in
men on active surveillance, but no cut-off could be agreed
upon. It was agreed that Gleason 4 + 3 or T3a disease or
any involvement of lymph nodes or bone metastases is
clinically significant. Some panellists deemed any Gleason
pattern 4 as significant; others felt that small-volume
secondary pattern 4 disease alone was not necessarily of
clinical significance in all men. PSA and PSA derivatives
such as PSA density and PSA doubling timewere deemed of
interest in determining clinically significant disease,
although again no threshold was identified.
It was acknowledged that clinical significance of MRI
lesions is also influenced by patient factors such as age and
comorbidities; a lesion may be deemed significant in a
younger man aged 50 yr but not in an older man with
several comorbidities.
3.8. Noteworthy areas of uncertainty
There was no agreement on the best way to present change
in lesion size or appearance over time across a cohort of
men. It was acknowledged that some lesions become
nonvisible during follow-up, and there was uncertainty
over how best to deal with this when aggregating results
across a cohort. Concern was expressed that use of
percentage change of lesion volume across a cohort
could yield a large percentage change in small lesions (eg,
a 0.1-cm3 lesion increasing to a 0.3-cm3 lesion) and thereby
skew results across the cohort. It was also noted that the
measurement errors of small lesions could be larger than any
change, even if significant in percentage terms.
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standard biopsy and/or targeted biopsy should be
performed on men with MRI changes. Some felt that a
man eligible for treatment at the start of the surveillance
period (eg, small-volume Gleason 3 + 4 disease) would
not require additional biopsy confirmation for a minor
radiologic change. Although some expressed a wish for
biopsy verification of suspected MRI-depicted disease
progression, it was recognised that patients and clinicians
may reasonably opt for treatment without further biopsy.
4. Discussion
4.1. Summary of results
The PRECISE checklist outlines key information that
researchers should report in a study of a cohort of men
having an MRI on active surveillance for PCa. The PRECISE
case report form is designed for clinical radiologists to
report an individual MRI at baseline or follow-up. Use of the
case report form will ensure that appropriate data are
collected to inform cohort reporting.
The number of statements scored with agreement and
consensus reduced from pre-meeting scoring to scoring at
the meeting. The purpose of the face-to-face element of a
formal consensusmeeting is to allow detailed discussion and
interaction of the panellists to fully explore a topic. This can
reduce or increase consensus. The reduced number of
statements with agreed consensus showed that many
challenging topics were discussed in an area in which data
are emerging.
4.2. Clinical and research implications
MRI is being used more frequently in men on active
surveillance to assess for clinically significant disease
missed at initial biopsy or to reduce the need for repeat
biopsy [8]. There are data to suggest that stability on MRI
can predict Gleason score stability [9].
The use of MRI in men on active surveillance varies
between countries and health systems, with a lower use of
MRI outside of academic centres [10]. Some centres exclude
men with visible lesions on MRI from an active surveillance
programme to reduce the likelihood of unfavourable
pathology [11,12]. It is known that some small lesions on
prostate MRI can be pathologically benign or of a low-grade
tumour only [13]. However, others recognise that it is likely
that long established active surveillance series would no
doubt have included men who would have had visible
lesions on MRI had it been available at that time, and
treatment of all men with MRI-visible disease is likely to
lead to significant overtreatment. Data have shown that
men with a visible lesion (positive MRI) are more likely to
receive treatment thanmenwith a negativeMRI. The extent
towhich clinical decisionsmay have been influenced by this
factor is not easy to determine because there are few studies
in which clinicians were blinded to MRI results.
We hope that use of the PRECISE checklist will allow the
natural history ofMRI changes inmen on active surveillanceto become clearer, allowing appropriate significance
thresholds for radiologic disease to be set both at baseline
and during surveillance. The correlation of radiologic
findings with PSA and histologic data, and treatment-free
survival will also be of great value. The use of the PRECISE
recommendations to analyse large data sets such as those
from the Movember Global Action Project on Active
Surveillance [14] would allow rapid assessment and
refinement of the recommendations based on data from
multiple centres worldwide.
4.3. Limitations
The greatest limitation of these recommendations is the
lack of published data on which they are based. The
intention of these recommendations is that they will allow
robust data collection in those areas deemed most
important by expert opinion, so that further iterations will
be based on those data. The areas most in need of research
are the optimal way of measuring lesion size to allow
repeatability over time and both the change in size and
absolute size that should prompt clinical action. Although
there is a possibility of bias in the groups selected for the
consensusmeeting, only a small number of centres declined
the invitation to participate.
5. Conclusions
The PRECISE recommendations were developed to facilitate
robust data collection and thus assess the natural history of
MRI findings in men on active surveillance. If widely used,
the data derived will facilitate the determination of
thresholds that identify radiologically significant disease
and important radiologic changes on MRI. It is likely that
initial validation work will lead to refinement of the
recommendations in due course.
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